FDA Approves, Leqembi, New Treatment for Early Alzheimer’snews2023-01-06T22:58:48+00:00January 6th, 2023|The New York Times|
Congressional Investigation into Alzheimer’s Drug Aduhelm Faults the F.D.A. and Biogennews2022-12-29T19:54:35+00:00December 29th, 2022|The New York Times|
What A.L.S. and Alzheimer’s Drug Approvals Have in Commonnews2022-10-14T19:10:06+00:00October 14th, 2022|The New York Times|
Alzheimer’s Drug Slows Cognitive Decline in Key Studynews2022-09-28T13:42:59+00:00September 28th, 2022|The New York Times|
Biogen C.E.O. to Step Down Following Launch of Alzheimer’s Drug, Aduhelmnews2022-05-03T18:00:36+00:00May 3rd, 2022|The New York Times|
Medicare Officially Limits Coverage of Aduhelm to Patients in Clinical Trialsnews2022-04-07T23:32:59+00:00April 7th, 2022|The New York Times|
Inside a Campaign to Get Medicare Coverage for a New Alzheimer’s Drugnews2022-04-06T18:43:00+00:00April 6th, 2022|The New York Times|
F.D.A. Rushed a Drug for Preterm Births. Did It Put Speed Over Science?news2022-03-25T15:15:07+00:00March 25th, 2022|The New York Times|
Senate Confirms Califf as F.D.A. Chief in Tight Votenews2022-02-15T18:47:59+00:00February 15th, 2022|The New York Times|
Medicare Proposes to Sharply Limit Coverage of the Alzheimer’s Drug Aduhelmnews2022-01-12T01:22:10+00:00January 12th, 2022|The New York Times|